Micafungin Hikma (Micafungin)

Micafungin is an echinocandin antifungal indicated for several serious fungal infections.

• Invasive candidiasis: effective in treating bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: clears Candida infection of the esophagus in immunocompromised patients.
• Candidemia: eliminates Candida species from the bloodstream.
• Prophylaxis of fungal infections in neutropenic patients: prevents invasive fungal disease during chemotherapy‑induced neutropenia.

• Micafungin inhibits the synthesis of β‑(1,3)‑D‑glucan, an essential polysaccharide component of the fungal cell wall. By blocking the enzyme β‑(1,3)‑D‑glucan synthase, it weakens cell wall integrity, leading to osmotic instability and cell lysis. This mechanism is selective for fungi, as human cells lack β‑(1,3)‑D‑glucan, resulting in targeted antifungal activity without affecting mammalian cells.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate headache.
• Elevated liver enzymes: mild increases in ALT or AST.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring monitoring.
• Anaphylaxis: acute allergic reaction with respiratory distress.
• Severe hypotension: sudden drop in blood pressure.
• Renal impairment: acute kidney injury in susceptible patients.

When using Micafungin, clinicians should observe several safety considerations.

• Liver function monitoring: check ALT, AST, bilirubin before and during therapy.
• Renal function assessment: evaluate creatinine clearance in patients with kidney disease.
• Drug interaction review: assess concomitant use of cytochrome P450 modulators.
• Pregnancy and lactation: avoid unless benefits outweigh potential risks, as safety data are limited.
• Use in pediatric patients: dose adjustment may be required based on weight and age.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its concentration or safety.

Major Interactions (Avoid)

• Cyclosporine: co‑administration increases micafungin exposure, raising toxicity risk.
• Rifampin: induces metabolism, markedly reducing micafungin levels and efficacy.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may alter plasma concentrations, requiring monitoring.
• Warfarin: potential for altered anticoagulant effect, monitor INR.
• Statins (e.g., simvastatin): increased risk of myopathy, observe muscle symptoms.
• Immunosuppressants (e.g., tacrolimus): possible concentration changes, adjust dosing as needed.